Human Trials
Intratumoral injection volume directly affects drug distribution within the tumour. EBC-46 trial protocols reveal how researchers calibrate dosing to maximise coverage and treatment response.
Human Trials
How clinical researchers quantify tumour response to tigilanol tiglate treatment, from RECIST criteria to volumetric imaging and histological confirmation.
Human Trials
Phase I dose-escalation studies follow strict protocols to identify safe dosing ranges. Here is how EBC-46 researchers approached this challenge in early-stage clinical work.
Human Trials
Clinical trials of tigilanol tiglate use strict inclusion and exclusion criteria to identify patients most likely to respond safely, shaping the evidence base for EBC-46 research.
Human Trials
The jump from compelling preclinical data to demonstrated human efficacy is one medicine's most treacherous crossings. For tigilanol tiglate (EBC-46), the published human trial evidence comes from a Phase I/II study led by QBiotics Group, published in the journal Cancers in late 2020. Understanding what this data
Human Trials
How EBC-46 behaves after intratumoral injection — drug retention within the tumour mass, local diffusion patterns, and why systemic exposure remains minimal.
EBC-46
Clinical trial data reveals a consistent pattern of local adverse events following tigilanol tiglate injection, including pain, swelling, and wound formation that resolve over weeks.
Human Trials
Phase I trial data shows that wound healing after intratumoral EBC-46 injection follows a predictable pattern, with most treated sites closing within four to six weeks.
EBC-46
Phase I human trials of tigilanol tiglate are evaluating safety in solid tumours. Early data suggests the tolerability profile mirrors what was observed in veterinary studies.